{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:41:06Z","timestamp":1769053266349,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing","doi-asserted-by":"crossref","award":["7151001"],"award-info":[{"award-number":["7151001"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Foundation of Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases","award":["2015DXWL03"],"award-info":[{"award-number":["2015DXWL03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10557-018-6831-9","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T23:54:16Z","timestamp":1539647656000},"page":"541-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats"],"prefix":"10.1007","volume":"32","author":[{"given":"Yi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuli","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"6831_CR1","unstructured":"Cho NH, Kirigia J, Mbanya JC, Ogurstova K, Guariguata L, Rathmann W, et al. IDF DIABETES ATLAS. 8th ed. International Diabetes Federation; 2017."},{"key":"6831_CR2","doi-asserted-by":"crossref","unstructured":"R\u00f6hrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6.","DOI":"10.3389\/fimmu.2015.00386"},{"issue":"3","key":"6831_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"key":"6831_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","volume":"3","author":"PA Read","year":"2010","unstructured":"Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195\u2013201.","journal-title":"Circ Cardiovasc Imaging"},{"key":"6831_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1161\/CIRCIMAGING.113.000785","volume":"7","author":"LM McCormick","year":"2014","unstructured":"McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7:274\u201381.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"6831_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","volume":"16","author":"H Yamada","year":"2017","unstructured":"Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16(1):63.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"6831_CR7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jacc.2006.07.022","volume":"48","author":"L Cai","year":"2006","unstructured":"Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;48(8):1688\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"6831_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/cdd.2014.150","volume":"22","author":"G Filomeni","year":"2015","unstructured":"Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377\u201388.","journal-title":"Cell Death Differ"},{"issue":"9","key":"6831_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/cbin.10626","volume":"40","author":"Y Yang","year":"2016","unstructured":"Yang Y, Zhao C, Yang P, Wang X, Wang L, Chen A. Autophagy in cardiac metabolic control: novel mechanisms for cardiovascular disorders. Cell Biol Int. 2016;40(9):944\u201354.","journal-title":"Cell Biol Int"},{"issue":"7182","key":"6831_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature06639","volume":"451","author":"N Mizushima","year":"2008","unstructured":"Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069\u201375.","journal-title":"Nature"},{"key":"6831_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.yjmcc.2014.12.017","volume":"83","author":"PJ Linton","year":"2015","unstructured":"Linton PJ, Gurney M, Sengstock D, Mentzer RM Jr, Gottlieb RA. This old heart: cardiac aging and autophagy. J Mol Cell Cardiol. 2015;83:44\u201354.","journal-title":"J Mol Cell Cardiol"},{"key":"6831_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1055\/s-0031-1284383","volume":"43","author":"Y Ishibashi","year":"2011","unstructured":"Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res. 2011;43:731\u20134.","journal-title":"Horm Metab Res"},{"key":"6831_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1089\/ars.2013.5519","volume":"21","author":"L Liu","year":"2014","unstructured":"Liu L, Liu J, Tian XY, Wong WT, Lau CW, Xu A, et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal. 2014;21:1571\u201381.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"6831_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/1074248417715001","volume":"23","author":"H Wang","year":"2018","unstructured":"Wang H, Zhou Y, Guo Z, Dong Y, Xu J, Huang H, et al. Sitagliptin attenuates endothelial dysfunction of Zucker diabetic fatty rats: implication of the antiperoxynitrite and autophagy. J Cardiovasc Pharmacol Ther. 2018;23(1):66\u201378.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"6831_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kr\u00f6ller-Sch\u00f6n S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385.","journal-title":"Redox Biol"},{"key":"6831_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","volume":"41","author":"D Williams","year":"2002","unstructured":"Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"6831_CR17","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1185\/030079906X132587","volume":"22","author":"GA Herman","year":"2006","unstructured":"Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22:1939\u201347.","journal-title":"Curr Med Res Opin"},{"key":"6831_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/0091270009341653","volume":"49","author":"DH Wright","year":"2009","unstructured":"Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 2009;49:1157\u201367.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"6831_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40265-013-0169-1","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(2):223\u201342.","journal-title":"Drugs"},{"issue":"6","key":"6831_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1586\/14779072.2015.1046840","volume":"13","author":"M Lee","year":"2015","unstructured":"Lee M, Rhee MK. Sitagliptin for type 2 diabetes: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(6):597\u2013610.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"6831_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.5551\/jat.41343","volume":"25","author":"D Masuda","year":"2017","unstructured":"Masuda D, Kobayashi T, Sairyou M, Hanada H, Ohama T, Koseki M, et al. Effects of a dipeptidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (GLORIA trial). J Atheroscler Thromb. 2017;25:512\u201320.","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"6831_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/HYPERTENSIONAHA.117.09482","volume":"70","author":"AM Navar","year":"2017","unstructured":"Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, et al. Hypertension control in adults with diabetes mellitus and recurrent cardiovascular events: global results from the trial evaluating cardiovascular outcomes with sitagliptin. Hypertension. 2017;70(5):907\u201314.","journal-title":"Hypertension"},{"key":"6831_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.12659\/AJCR.900620","volume":"17","author":"Y Saito","year":"2016","unstructured":"Saito Y, Ishikawa J, Harada K. Postprandial and orthostatic hypotension treated by sitagliptin in a patient with dementia with Lewy bodies. Am J Case Rep. 2016;17:887\u201393.","journal-title":"Am J Case Rep"},{"issue":"3","key":"6831_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2011.07.053","volume":"59","author":"J Matsubara","year":"2012","unstructured":"Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59(3):265\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"6831_CR25","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1476-5381.2012.02102.x","volume":"167","author":"CY Huang","year":"2012","unstructured":"Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol. 2012;167(7):1506\u201319.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"6831_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.112.195115","volume":"60","author":"L Liu","year":"2012","unstructured":"Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60(3):833\u201341.","journal-title":"Hypertension"},{"key":"6831_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2013.12.036","volume":"723","author":"B Hemmeryckx","year":"2014","unstructured":"Hemmeryckx B, Swinnen M, Gallacher DJ, Rong LH, Roger LH. Effect of sitagliptin treatment on metabolism and cardiac function in genetically diabetic mice. Eur J Pharmacol. 2014;723:175\u201380.","journal-title":"Eur J Pharmacol"},{"key":"6831_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cvr\/cvu223","volume":"104","author":"N Hamdani","year":"2014","unstructured":"Hamdani N, Hervent AS, Vandekerckhove L, Matheeussen V, Demolder M, Baerts L, et al. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res. 2014;104:423\u201331.","journal-title":"Cardiovasc Res"},{"key":"6831_CR29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.5114\/aoms.2017.68143","volume":"13","author":"X Ke","year":"2017","unstructured":"Ke X, Ke B, Wang X, Wu S, Yang R, Hu C. Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study. Arch Med Sci. 2017;13:956\u201361.","journal-title":"Arch Med Sci"},{"key":"6831_CR30","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2147\/DDDT.S109287","volume":"10","author":"NM Al-Rasheed","year":"2016","unstructured":"Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM. Sitagliptin attenuates cardiomyopathy by modulating the JAK\/STAT signaling pathway in experimental diabetic rats. Drug Des Devel Ther. 2016;10:2095\u2013107.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"6831_CR31","doi-asserted-by":"publisher","first-page":"H1454","DOI":"10.1152\/ajpheart.00867.2009","volume":"298","author":"Y Ye","year":"2010","unstructured":"Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454\u201365.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6831_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejphar.2013.09.007","volume":"718","author":"G Chang","year":"2013","unstructured":"Chang G, Zhang P, Ye L, Lu K, Wang Y, Duan Q, et al. Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia\/reperfusion rat model. Eur J Pharmacol. 2013;718:105\u201313.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"6831_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1042\/CS20170010","volume":"131","author":"B Maiztegui","year":"2017","unstructured":"Maiztegui B, Boggio V, Rom\u00e1n CL, Flores LE, Zotto HD, Ropolo A, et al. VMP1-related autophagy induced by a fructose-rich diet in \u03b2-cells: its prevention by incretins. Clin Sci (Lond). 2017;131(8):673\u201387.","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"6831_CR34","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1159\/000438552","volume":"37","author":"XM Wang","year":"2015","unstructured":"Wang XM, Yang YJ, Wu YJ, Zhang Q, Qian HY. Attenuating hypoxia-induced apoptosis and autophagy of mesenchymal stem cells: the potential of sitagliptin in stem cell-based therapy. Cell Physiol Biochem. 2015;37(5):1914\u201326.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"6831_CR35","doi-asserted-by":"publisher","first-page":"C617","DOI":"10.1152\/ajpcell.00296.2012","volume":"304","author":"HJ Wang","year":"2013","unstructured":"Wang HJ, Zhang D, Tan YZ, Li T. Autophagy in endothelial progenitor cells is cytoprotective in hypoxic conditions. Am J Phys Cell Phys. 2013;304(7):C617\u201326.","journal-title":"Am J Phys Cell Phys"},{"key":"6831_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2840-12-53","volume":"12","author":"E Leibovitz","year":"2013","unstructured":"Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol. 2013;12:53.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"6831_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","volume":"110","author":"S Steven","year":"2015","unstructured":"Steven S, Hausding M, Kr\u00f6ller-Sch\u00f6n S, Mader M, Mikhed Y, Stamm P, et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol. 2015;110(2):6.","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"6831_CR38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/HJH.0b013e328341939d","volume":"29","author":"BP Pacheco","year":"2011","unstructured":"Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011;29(3):520\u20138.","journal-title":"J Hypertens"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6831-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:19:40Z","timestamp":1571167180000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6831-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["6831"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6831-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"16 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving animals were in accordance with the \u201cGuiding Principles in the Use and Care of Animals\u201d published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and approved by the Institutional Animal Care and Use Committee of Capital Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Animals"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All subjects have been informed of the purpose and nature of this study and given written informed consents. The study was approved by the local research ethics committee (Beijing Anzhen Hospital, Capital Medical University, Beijing, China).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}}]}}